Alliances
Dubai South has signed a Memorandum of Understanding (MOU) with the UAE Ministry of Health and Prevention (MOHAP) as part of its efforts to strengthen cooperation with the pharmaceutical sector and enable pharmaceutical companies to take advantage of the opportunities to operate within Dubai South.
The quantitative next-generation sequencing blood test for infectious diseases makes an international impact
Cambridge, Mass.-based Biogen exercised its option to acquire additional shares of South Korea’s Samsung Bioepis. Samsung Bioepis focuses on developing biosimilar drugs and is a joint venture between Samsung Biologics and Biogen formed in 2012.
Nektar Therapeutics, based in San Francisco, and New York-based Pfizer are teaming up to evaluate combination regimens in several cancer settings. Those include metastatic castration-resistant prostate cancer (mCRPC) and squamous cell carcinoma of the head and heck (SCCHN).
Janssen agreed to pay Yuhan $50 million in upfront money. Yuhan said that Janssen will be responsible for the development of lazertinib. Janssen will also be responsible for manufacturing and commercialization of the drug.
Lilly is paying NextCure $25 million upfront. NextCure will be eligible for various development and commercial milestone payments, as well as royalties on any commercial products. In addition, Lilly invested $15 million in NextCure equity.
Acting on an option out of 2016 collaboration deal, Japan’s Takeda Pharmaceutical licensed Humabodies directed to one of its oncology targets from Cambridge, UK’s Crescendo Biologics.
A study evaluated fixed-duration the two companies’ Venclexta/Venclyxto (venetoclax) in combination with Genentech’s Gazyva/Gazyvaro (obinutuzumab) in patients with previously untreated chronic lymphocytic leukemia (CLL) and co-existing medical conditions.
Shares of Denali Therapeutics are up more than 10 percent in premarket trading after the company announced it has inked a collaborative deal with Sanofi to develop potential treatments for neurological and systemic inflammatory diseases.
The deal, which will last several years, has Tango performing target discovery and validation. Gilead will be able to option rights to up to five targets that come out of Tango’s work.
PRESS RELEASES